SK Life Science Inc., a subsidiary of South Kore-based SK Biopharmaceuticals Co. Ltd, announced on Thursday that it has received US Food and Drug administration (FDA) approval for the investigational new drug (IND) application to study SKL27969 as a potential treatment for advanced solid tumours.
The company is to carry out a Phase 1/2 open-label, non-randomised, multicentre, dose escalation and expansion study aimed at assessing the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of SKL27969 in adult patients with solid tumours.
Marc Kamin, MD, chief medical officer at SK life science, said, 'We look forward to learning more about the potential of SKL27969 as a treatment option for a range of advanced solid tumours. We are excited to expand our R&D efforts into discovering potential new therapies for cancer.'
Pfizer and BioNTech granted US EUA for booster dose of their COVID-19 vaccine in children 5 to 11
New data from Sanofi's oncology pipeline and portfolio to be presented at 2022 ASCO Annual Meeting
Vertex awards USD50m in grants to to JDRF, Mass General and Year Up
UK Grants Licence for Teva's Ophthalmology Biosimilar Ongavia
First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors